23 hrs ago
Salix Pharmaceuticals (SLXP) - Research Analysts' Recent Ratings Updates
Salix Pharmaceuticals had its price target raised by analysts at UBS AG from $94.00 to $110.00.
Trending on the Topix Network
Thu Mar 06, 2014
Napo Loses Lawsuit Against Salix Over Diarrhea Drug
Napo Pharmaceuticals has lost its lawsuit against Salix Pharmaceuticals, in which the biotech firm accused Salix of deliberately thwarting the success of Fulyzaq , the first-ever drug approved to treat diarrhea related to HIV meds.
Wed Mar 05, 2014
Pharming Reports On Preliminary Financial Results 2013
Leiden, The Netherlands, 6 March 2014 . Biotech company Pharming Group NV today published its preliminary financial results for the year ended 31 December 2013.
Tue Mar 04, 2014
Investor's Business Daily
Salix Pharmaceuticals to Present at ROTH Conference
Salix Pharmaceuticals, Ltd. today announced that the Company will present at the 26th Annual ROTH Conference in Laguna Niguel, CA on Tuesday, March 11, 2014 at 1:30 p.m. PT .
Fri Feb 28, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
Agenus executives will ho... )--Capital Senior Living Corporation , one of the country's largest operators of senior living communities, today announced operating and financial r... )--Oak Ridge Energy Technologies, Inc. today announced the formation of its Business Advisory Committee .
Thu Feb 27, 2014
Salix Pharmaceuticals Reports 4Q2013 and FY2013 Results
The fourth quarter does not include results for the Company's acquisition of For the fourth quarter of 2013, as compared to the fourth quarter of 2012, total product revenue increased 30% to Important disclosures about reconciliations of applicable GAAP reported to non-GAAP adjusted information are included in this press release.
Salix Pharmaceuticals Management Discusses Q4 2013 Results - Earnings Call Transcript
Good day, and welcome to the Salix Pharmaceuticals Fourth Quarter and Full Year 2013 Conference Call.
Salix Pharmaceuticals (SLXP) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS
Salix Pharmaceuticals announced its earnings results on Thursday. The company reported $1.06 earnings per share for the quarter, beating the analysts' consensus estimate of $0.93 by $0.13, Analyst RN reports.
Salix Pharmaceuticals, Ltd., RedHill Biopharma Ltd. Enter Game-Changing Bowel Prep Agreement
Salix Pharmaceuticals and RedHill Biopharma Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation RALEIGH, N.C.-- --Salix Pharmaceuticals Ltd. and RedHill Biopharma Ltd. today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to ... (more)
Local Tech Wire
Salix strikes $12M licensing deal for bowel prep drug
The deal, which was announced early Thursday, calls for Salix to pay an upfront fee of $7 million and $5 million in milestone payments plus royalties.
Tue Feb 25, 2014
Salix Wins Napo Pharmaceuticals Litigation
The jury specifically found that Salix complied with its contractual obligations in commercializing Fulyzaq in the United States, and thus did not breach the license agreement between the parties.
Salix prevails in lawsuit with partner
A New York jury ruled in Salix Pharmaceuticals' favor in a case brought against the drug company from one of its partners.
Salix Pharmaceuticals Receives Consensus Rating of "Hold" from Analysts
Salix Pharmaceuticals has received an average rating of "Hold" from the sixteen analysts that are presently covering the stock, AnalystRatings.Net reports .
Mon Feb 24, 2014
NASDAQ Gainers Watch List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)...
Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Arena Pharmaceuticals, Inc. and Salix Pharmaceuticals Ltd. .
Sun Feb 23, 2014
Pharming and Salix Announce Extension of Pdufa Action Date for Ruconest
Pharming Group NV and Salix Pharmaceuticals, Ltd. today announced that the Food and Drug Administration has extended the Prescription Drug User Fee Act Action Date to July 16, 2014 for the Company's Biologics License Application for the investigational drug RUCONEST 50 IU/kg.
Salix and Pharming Announce Extension of PDUFA Action Date for RUCONEST
Salix and Pharming are seeking U.S. marketing approval of RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema .
Tue Feb 18, 2014
Investor's Business Daily
Stocks Struggle In Mixed Trade; Salix, HollySys Advance
Stocks opened mixed and under pressure Tuesday as a weak reading on January housing compounded soft data on New York region manufacturing.
Thu Feb 13, 2014
Recently released market study: Oceana Therapeutics, Inc. -...
Oceana Therapeutics is a pharmaceutical company which deals in Specialty Treatment and Physician Care Management.
Investor's Business Daily
Salix Pharmaceuticals Announces 4Q and FY2013 Financial Results...
Salix Pharmaceuticals, Ltd. today announced that the Company will report fourth quarter and full year 2013 financial results following the close of the U.S. financial markets on Thursday, February 27, 2014.
Tue Feb 11, 2014
Salix Pharmaceuticals Sets New 52-Week High at $103.67
Salix Pharmaceuticals hit a new 52-week high on Tuesday , Analyst Ratings Network.com reports.